Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 4.47 CAD -4.89% Market Closed
Market Cap: 205.5m CAD

EV/EBITDA
Enterprise Value to EBITDA

17.2
Current
4.5
Median
6.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
17.2
=
Enterprise Value
247.2m CAD
/
EBITDA
10.4m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
CA
Theratechnologies Inc
TSX:TH
Average EV/EBITDA: 37.7
17.2
47%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 797.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
AU
CSL Ltd
ASX:CSL
13
8%
1.6
NL
argenx SE
XBRU:ARGX
61.6
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.8
N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
14.5
2-Years Forward
EV/EBITDA
6.6
3-Years Forward
EV/EBITDA
5.1